Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chidamide + gemcitabine + vinorelbine + mitoxantrone hydrochloride liposome
- Development stage
- Unknown
- Lead developer
- Jiangsu Provincial People's Hospital
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Chi-GVM is a combination chemotherapy regimen investigated for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). The regimen consists of chidamide (tucidinostat), gemcitabine, vinorelbine, and mitoxantrone hydrochloride liposome. Chidamide is an orally active, subtype-selective histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, vinorelbine is a vinca alkaloid that disrupts microtubule assembly, and mitoxantrone hydrochloride liposome is an anthracenedione antineoplastic agent that intercalates into DNA and inhibits topoisomerase II. This multi-agent approach is designed to overcome the poor prognosis and limited durability of standard anthracycline-based therapies in patients with mature T-cell malignancies.
- Other names
- Chi-GVM regimen
02
Targets
DNADNA polymerase familyTOP2A (DNA topoisomerase II)HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC11 (Histone Deacetylase 11)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)PKC (Protein kinase C family)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on chidamide + gemcitabine + vinorelbine + mitoxantrone hydrochloride liposome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chidamide + gemcitabine + vinorelbine + mitoxantrone hydrochloride liposome.